| Home | E-Submission | Sitemap | Contact Us |  
logo
Korean J Med > Volume 88(6); 2015 > Article
소화기
The Korean Journal of Medicine 2015;88(6): 623-629.
만성 C형 간염 진료 가이드라인 비교
김경아
인제대학교 의과대학 일산백병원 내과
Comparison of Guidelines for Management of Chronic Hepatitis C
Kyung-Ah Kim
Department of Internal Medicine, Ilsan Paik Hospital, Inje University College of Medicine, Goyang, Korea
Corresponding Author: Kyung-Ah Kim ,Tel: +82-31-910-7847, Fax: +82-31-910-7219, Email: kakim@ilsanpaik.ac.kr
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
ABSTRACT
Therapeutic options for patients with hepatitis C virus infection have evolved substantially with the advent of highly effective direct-acting antiviral agents (DAA). Guidelines for treatment of hepatitis C have changed with the evolution of hepatitis C treatments. However, it differs considerably among nations, as the approval and availability of new DAAs, cost-effectiveness, socioeconomic status, and timing of guideline revisions vary. Guidelines for management of hepatitis C by the Korean Association for the Study of the Liver, which was established in November 2013, recommend response-guided therapy with combination of peg-interferon-α and ribavirin (PR). Recommendations for testing, managing, and treating hepatitis C by the American Association for the Study of Liver Disease, which was established in January 2014 and keeps updated, recommend the combination therapy including new DAAs such as sofosbuvir, ledipasvir/sofosbuvir, simeprevir and ritonavir-boosted paritaprevir/ombitasvir/dasabuvir, and discourage use of PR with or without a first-generation protease inhibitor. The European Association of the Study of the Liver recommendations for treatment of hepatitis C revised in April 2015 suggest combination therapy, including new DAAs, such as sofosbuvir, ledipasvir/sofosbuvir, simeprevir, daclatasvir, and ritonavir-boosted paritaprevir/ombitasvir/dasabuvir. Guidelines for treating hepatitis C will be changing soon in Korea with the approval and release of new DAAs.
Keywords: Guideline; Hepatitis C; Treatment; Direct-acting antivirals
Editorial Office
101-2501, Lotte Castle President, 109 Mapo-daero, Mapo-gu, Seoul 04146, Korea
Tel: +82-2-2271-6791   Fax: +82-2-790-0993    E-mail: kaim@kams.or.kr
About |  Browse Articles |  Current Issue |  For Authors and Reviewers
Copyright © The Korean Association of Internal Medicine. All rights reserved.                powerd by m2community